Development of chitosan–pullulan composite nanoparticles for nasal delivery of vaccines: in vivo studies

References

• Abbas AK, Lichtman AH. 2006. Basic immunology. 2nd ed. Philadelphia, PA: Elsevier Store
   Google Scholar
• Almeida AJ, Alpar HO. Nasal delivery of vaccines. J Drug Target, 1996;3:455–67
   PubMed Web of Science ®Google Scholar
• Alpar HO, Eyles JE, Williamson ED, Somavarapu S. Intranasal vaccination against plague, tetanus and diphtheria. Adv Drug Deliver Rev, 2001;51:173–201
   PubMed Web of Science ®Google Scholar
• Alpar HO, Somavarapu S, Atuah KN, Bramwell V. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliver Rev, 2005;57:411–30
   PubMed Web of Science ®Google Scholar
• Amidi M, Romeijn SG, Borchard G, Junginger HE, Hennink WE, Jiskoot W. Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. J Control Release, 2006;111:107–16
   PubMed Web of Science ®Google Scholar
• Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, Huckriede A, Crommelin DJA, Jiskoot W. N-Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: Biological properties and immunogenicity in a mouse model. Vaccine, 2007;25:144–53
   PubMed Web of Science ®Google Scholar
• Baudner BC, Morandi M, Giuliani MM, Verhoef JC, Junginger HE, Costantino P, Rappuoli R, Del Giudice G. Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system. J Infect Dis, 2004;189:828–32
   PubMed Web of Science ®Google Scholar
• Baylor NW, Egan W, Richman P. Aluminum salts in vaccines-US perspective. Vaccine, 2002;20:S18–23
   PubMed Web of Science ®Google Scholar
• Bendelac A, Fearon DT. Innate pathways that control acquired immunity. Curr Opin Immunol, 1997;9:1–3
   PubMed Web of Science ®Google Scholar
• Biedermann T, Röcken M, Carballido JM. TH1 and TH2 lymphocyte development and regulation of TH cell-mediated immune responses of the skin. J Invest Dermatol Symp Proceed, 2004;9:5–14
   PubMed Web of Science ®Google Scholar
• Boonyo W, Junginger HE, Waranuch N, Polnok A, Pitaksuteepong T. Chitosan and trimethyl chitosan chloride (TMC) as adjuvants for inducing immune responses to ovalbumin in mice following nasal administration. J Control Release, 2007;121:168–75
   PubMed Web of Science ®Google Scholar
• Borges O, Silva M, de Sousa A, Borchard G, Junginger HE, Cordeiro-da-Silva A. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen. Int Immunopharmacol, 2008;8:1773–80
   PubMed Web of Science ®Google Scholar
• Borges O, Tavares J, de Sousa A, Borchard G, Junginger HE, Cordeiro-Da-Silva A. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. Eur J Pharm Sci, 2007;32:278–90
   PubMed Web of Science ®Google Scholar
• Cervi L, MacDonald AS, Kane C, Dzierszinski F, Pearce EJ. Cutting edge: Dendritic cells copulsed with microbial and helminth antigens undergo modified maturation, segregate the antigens to distinct intracellular compartments, and concurrently induce microbe-specific Th1 and helminth-specific Th2 responses. J Immunol, 2004;172(4):2016–20
   PubMed Web of Science ®Google Scholar
• Chen Q, Hu Y, Chen Y, Jiang XQ, Yang YH. Microstructure formation and property of chitosan-poly (acrylic acid) nanoparticles prepared by macromolecular complex. Macromol Biosci, 2005;5:993–1000
   PubMed Web of Science ®Google Scholar
• Chopra S, Mahdi S, Kaur J, Iqbal Z, Talegaonkar S, Ahmad FJ. Advances and potential applications of chitosan derivatives as mucoadhesive biomaterials in modern drug delivery. J Pharm Pharmacol, 2006;58:1021–32
   PubMed Web of Science ®Google Scholar
• Cleland JL. Single-administration vaccines: Controlled release technology to mimic repeated immunizations. Trends Biotechnol, 1999;17:25–9
   PubMed Web of Science ®Google Scholar
• Cooper CL, Dubin PL, Kayitmazer AB, Turksen S. Polyelectrolyte protein complexes. Curr Opin Colloid Interface Sci, 2005;10:52–78
   Web of Science ®Google Scholar
• Davis SS. Nasal vaccines. Adv Drug Deliver Rev, 2001;51:21–42
   PubMed Web of Science ®Google Scholar
• Davis SS. The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery. Vaccine, 2006;24:S7–10
   Web of Science ®Google Scholar
• de Vasconcelos CL, Bezerril PM, dos Santos DES, Dantas TNC, Pereira MR, Fonseca JLC. Effect of molecular weight and ionic strength on the formation of polyelectrolyte complexes based on poly(methacrylic acid) and chitosan. Biomacromolecules, 2006;7:1245–52
   PubMed Web of Science ®Google Scholar
• Diwan M, Tafaghodi M, Samuel J. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J Control Release, 2002;85:247–62
   PubMed Web of Science ®Google Scholar
• Freitas S, Merkle HP, Gander B. Microencapsulation by solvent extraction/evaporation: Reviewing the state of the art of microsphere preparation process technology. J Control Release, 2005;102:313–32
   PubMed Web of Science ®Google Scholar
• Fujimura Y, Akisada T, Harada T, Haruma K. Uptake of microparticles into the epithelium of human nasopharyngeal lymphoid tissue. Med Mol Morphol, 2006;39:181–6
   PubMed Web of Science ®Google Scholar
• Gupta RK. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev, 1998;32:155–72
   PubMed Web of Science ®Google Scholar
• Hartig SM, Greene RR, Dikov MM, Prokop A, Davidson JM. Multifunctional nanoparticulate polyelectrolyte complexes. Pharm Res, 2007;24:2353–69
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C, Eriksson K, Mharandi A. Mucosal immunisation and adjuvants: A brief overview of recent advances and challenges. Vaccine, 2003;21:S89–95
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med, 2005;11:S45–53
   PubMed Web of Science ®Google Scholar
• Horie K, Sakagami M, Masuda K, Notoya M, Hamana H, Yoshikawa T, Hirano K. Sialyl Lewis X-carboxymethylpullulan conjugate: A novel homing device to spleen and lymph nodes. Biol Pharm Bull, 2004;27:1275–80
   PubMed Web of Science ®Google Scholar
• Iho S, Maeyama J-I, Suzuki F. CpG oligodeoxynucleotides as mucosal adjuvants. Hum Vaccin Immunother, 2015;11:755–60
   PubMed Web of Science ®Google Scholar
• Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliver Rev, 2001;51:81–96
   PubMed Web of Science ®Google Scholar
• Janeway CA, Travers P, Walport M, Shlomchik MJ. 2005. Immunobiology. 6th ed. New York: Garland Science Publishing
   Google Scholar
• Johansen P, Estevez F, Zurbriggen R, Merkle HP, Gluck R, Corradin G, Gander B. Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres. Vaccine, 2000;19:1047–54
   PubMed Web of Science ®Google Scholar
• Kensil CR, Mo AXY, Truneh A. Current vaccine adjuvants: An overview of a diverse class. Front Biosci, 2004;9:2972–88
   PubMed Web of Science ®Google Scholar
• Kidd P. Th1/Th2 Balance: The hypothesis, its limitations, and implications for health and disease. Altern Med Rev, 2003;8:223–46
   PubMedGoogle Scholar
• Kotzé AF, LueBen HL, de Leeuw BJ, de Boer BG, Verhoef JC, Junginger HE. N-trimethyl chitosan chloride as a potential absorption enhancer across mucosal surfaces: In vitro evaluation in intestinal epithelial cells (Caco-2). Pharm Res, 1997;14:1197–202
   PubMed Web of Science ®Google Scholar
• Kovarik J, Bozzotti P, Tougne C, Davis HL, Lambert P-H, Krieg AM, Siegrist C-A. Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens. Immunology, 2001;102:67–76
   PubMed Web of Science ®Google Scholar
• Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov, 2006;5:471–84
   PubMed Web of Science ®Google Scholar
• Kuper CF, Koornstra PJ, Hameleers DMH, Biewenga J, Spit BJ, Duijvestijn AM, Vriesman PJC, Sminia T. The role of nasopharyngeal lymphoid-tissue. Immunol Today, 1992;13:219–24
   PubMedGoogle Scholar
• Lin C-Y, Lin S-J, Yang Y-C, Wang D-Y, Cheng H-F, Yeh M-K. Biodegradable polymeric microsphere-based vaccines and their applications in infectious diseases. Hum Vaccin Immunother, 2015;11:650–6
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhang C, Zheng X, Shao X, Zhang X, Zhang Q, Jiang X. Preparation and evaluation of antigen/N-trimethylaminoethylmethacrylate chitosan conjugates for nasal immunization. Vaccine, 2014;32:2582–90
   PubMed Web of Science ®Google Scholar
• Maeyama J, Takatsuka H, Suzuki F, Kubota A, Horiguchi S, Komiya T, Shimada I, Murata E, Osawa Y, Kitagawa H, et al. A palindromic CpG-containing phosphodiester oligodeoxynucleotide as a mucosal adjuvant stimulates plasmacytoid dendritic cell-mediated T(H)1 immunity. PLoS One, 2014;9:e88846
   PubMed Web of Science ®Google Scholar
• Mangal S, Pawar D, Garg NK, Jain AK, Vyas SP, Raman Rao DSV, Jaganathan KS. Pharmaceutical and immunological evaluation of mucoadhesive nanoparticles based delivery system(s) administered intranasally. Vaccine, 2011;29:4953–62
   PubMed Web of Science ®Google Scholar
• Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol, 2009;9:287–93
   PubMed Web of Science ®Google Scholar
• McCluskie MJ, Weeratna RD, Payette PJ, Davis HL. The potential of CpG oligodeoxynucleotides as mucosal adjuvants. Crit Rev Immunol, 2001;21:103–20
   PubMed Web of Science ®Google Scholar
• McNeela EA, O'Connor D, Jabbal-Gill I, Illum L, Davis SS, Pizza M, Peppoloni S, Rappuoli R, Mills KHG. A mucosal vaccine against diphtheria: Formulation of cross reacting material (CRM197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine, 2000;19:1188–98
   PubMed Web of Science ®Google Scholar
• Mitani S, Yamamoto A, Ikegami H, Usui M, Matuhasi T. Immunoglobulin E-suppressing and immunoglobulin G-enhancing tetanus toxoid prepared by conjugation with pullulan. Infect Immun, 1982;36:971–6
   PubMed Web of Science ®Google Scholar
• Mori T, Murakami M, Okumura M, Kadosawa T, Uede T, Fujinaga T. Mechanism of macrophage activation by chitin derivatives. J Vet Med Sci, 2005;67:51–6
   PubMed Web of Science ®Google Scholar
• Moschos SA, Bramwell VW, Somavarapu S, Alpar HO. Adjuvant synergy: The effects of nasal coadministration of adjuvants. Immunol Cell Biol, 2004;82:628–37
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Coffman RL. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol, 1989;46:111–47
   PubMed Web of Science ®Google Scholar
• Neutra MR, Kozlowski PA. Mucosal vaccines: The promise and the challenge. Nat Rev Immunol, 2006;6:148–58
   PubMed Web of Science ®Google Scholar
• Nils L. Recent progress in mucosal vaccine development: Potential and limitations. Nat Rev Immunol, 2012;12:592–605
   PubMed Web of Science ®Google Scholar
• O'Hagan DT. 2000. Vaccine adjuvants; Preparation methods and research protocols. Totowa, NJ: Humana Press
   Google Scholar
• Pandit S, Cevher E, Zariwala MG, Somavarapu S, Alpar HO. Enhancement of immune response of HBsAg loaded poly (L-lactic acid) microspheres against Hepatitis B through incorporation of alum and chitosan. J Microencapsul, 2007;24:539–52
   PubMed Web of Science ®Google Scholar
• Rajapaksa TE, Bennett KM, Hamer M, Lytle C, Rodgers VGJ, Lo DD. Intranasal M cell uptake of nanoparticles is independently influenced by targeting ligands and buffer ionic strength. J Biol Chem, 2010;285:23739–46
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med, 2006;54:11–22
   Web of Science ®Google Scholar
• Sánchez Vallecillo S, Ullio Gamboa GV, Palma SD, Harman MF, Chiodetti AL, Morón G, Allemandi DA, Pistoresi-Palencia MC, Maletto BA. Adjuvant activity of CpG-ODN formulated as a liquid crystal. Biomaterials, 2014;35:2529–42
   PubMed Web of Science ®Google Scholar
• Sayin B, Somavarapu S, Li XW, Thanou M, Sesardic D, Alpar HO, Senel S. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Int J Pharm, 2008;363:139–48
   PubMed Web of Science ®Google Scholar
• Schatz C, Domard A, Viton C, Pichot C, Delair T. Versatile and efficient formation of colloids of biopolymer-based polyelectrolyte complexes. Biomacromolecules, 2004;5:1882–92
   PubMed Web of Science ®Google Scholar
• Sharma R, Agrawal U, Mody N, Vyas SP. Polymer nanotechnology based approaches in mucosal vaccine delivery: Challenges and opportunities. Biotechnol Adv, 2015;33:64–79
   PubMed Web of Science ®Google Scholar
• Singh J, Pandit S, Bramwell VW, Alpar HO. Diphtheria toxoid loaded poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery systems. Methods, 2006;38:96–105
   PubMed Web of Science ®Google Scholar
• Slütter B, Bal SM, Ding Z, Jiskoot W, Bouwstra JA. Adjuvant effect of cationic liposomes and CpG depends on administration route. J Control Release, 2011;154:123–30
   PubMed Web of Science ®Google Scholar
• Sugumaran KR, Sindhu RV, Sukanya S, Aiswarya N, Ponnusami V. Statistical studies on high molecular weight pullulan production in solid state fermentation using jack fruit seed. Carbohydr Polym, 2013;98:854–60
   PubMed Web of Science ®Google Scholar
• Tafaghodi M, Tabassi SAS, Jaafari MR. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN. Int J Pharm, 2006;319:37–43
   PubMed Web of Science ®Google Scholar
• Thanou M, Verhoef JC, Junginger HE. Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliver Rev, 2001;52:117–26
   PubMed Web of Science ®Google Scholar
• Tsuji K, Fujimoto M, Masuko F, Nagase T. 1978. Carboxymethylated pullulan and method for producing same. US Patent 4090016
   Google Scholar
• Vajdy M, Srivastava I, Polo J, Donnelly J, O'Hagan D, Singh M. Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines. Immunol Cell Biol, 2004;82:617–27
   PubMed Web of Science ®Google Scholar
• van der Lubben IM, Kersten G, Fretz MM, Beuvery C, Verhoef JC, Junginger HE. Chitosan microparticles for mucosal vaccination against diphtheria: Oral and nasal efficacy studies in mice. Vaccine, 2003;21:1400–8
   PubMed Web of Science ®Google Scholar
• van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan for mucosal vaccination. Adv Drug Deliver Rev, 2001a;52:139–44
   PubMed Web of Science ®Google Scholar
• van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci, 2001b;14:201–7
   PubMed Web of Science ®Google Scholar
• van der Merwe SM, Verhoef JC, Verheijden JHM, Kotze AF, Junginger HE. Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs. Eur J Pharm Biopharm, 2004;58:225–35
   PubMed Web of Science ®Google Scholar
• Vila A, Sanchez A, Janes K, Behrens I, Kissel T, Jato JLV, Alonso MJ. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm, 2004;57:123–31
   PubMed Web of Science ®Google Scholar
• Wang X, Meng D. Innate endogenous adjuvants prime to desirable immune responses via mucosal routes. Protein Cell, 2015;6:170–84
   PubMedGoogle Scholar
• Woodrow KA, Bennett KM, Lo DD. Mucosal vaccine design and delivery. Annu Rev Biomed Eng, 2012;14:17–46
   PubMed Web of Science ®Google Scholar
• Wu KY, Wu M, Fu ML, Li H, Yang Y, Zhang H, Cheng C, Wang ZZ, Wang XY, Lu XB, et al. A novel chitosan CpG nanoparticle regulates cellular and humoral immunity of mice. Biomed Environ Sci, 2006;19:87–95
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang X, Csencsits KL, Haddad A, Walters N, Pascual DW. M cell-targeted DNA vaccination. Proc Natl Acad Sci USA, 2001;98:9318–23
   PubMed Web of Science ®Google Scholar
• Yamaya S, Yamamoto A, Komiya T, Mizuguchi J, Matuhasi T. Preparation of a diphtheria-toxin pullulan conjugate that elicits good IgG antibody production with poor IgE synthesis. Vaccine, 1990;8:65–9
   PubMed Web of Science ®Google Scholar